Journal
DRUG RESISTANCE UPDATES
Volume 7, Issue 3, Pages 169-184Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.drup.2004.04.003
Keywords
cyclooxygenase; lung cancer; celecoxib; clinical trials
Categories
Funding
- NCI NIH HHS [P50 CA90388] Funding Source: Medline
- NHLBI NIH HHS [1T32HL6699201] Funding Source: Medline
Ask authors/readers for more resources
Lung cancer is the leading cause of cancer death in the United States. Although the low 5-year survival rate (under 15%) has changed minimally in the last 25 years, new agents and combinations of agents that target tumor proliferation, invasion, and survival may lead to improvement in patient outcomes. There is evidence that cyclooxygenase-2 (COX-2) is overexpressed in lung cancer and promotes tumor proliferation, invasion, angiogenesis, and resistance to apoptosis. COX-2 inhibitors have been found to inhibit tumor growth in animal models and have demonstrated responses when combined with conventional therapy in phase II clinical trials. Further understanding of the mechanisms involved in COX-2-mediated tumorigenesis and its interaction with other molecules in lung cancer may lead to improved therapeutic strategies for this disease. In addition, delineation of how COX-2-dependent genes modulate the malignant phenotype will provide novel insights in lung cancer pathogenesis. (C) 2004 Elsevier Ltd. All fights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available